1Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus Cisplatin compared with Etoposide plus Cisplatin for extensive small-cell lung cancer [J]. N Engl J Med, 2002,346 (2): 85-91.
2Hanna N, Bunn PA, Langer C, et al. Randomized phase m trial comparing Irinotecan/Cisplatin with Etoposide/Cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer [J]. J Clin Oncol, 2006,24 (13) : 2038- 2043,.
3Lara PN Jr, Natale R, Crowley J, et al. Phase m trial of Irinotecan/Cisplatin compared with Etoposide/Cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacoge- nomic results from SWOG S0124 [J]. J Clin Oncol, 2009,27 (15) :2530-2535.
4Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing Irinotecan/Platinum with Etoposide/Platinum in patients with previously untreated extensive-stage small cell lung cancer [J]. J Thorac Oncol, 2010,5 (6) : 867-873.
8Ota K. Nedaplaptin[J].Japanese Journal of Cancer Chemotherapy,1996,(03):379-387.
9Yee D, Butts C, Reiman A, et al. Clinical trial of post- chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer[J].Radiother Oncol, 2012; 102(2):234-238.
10Califano R, Abidin AZ, Peck R, et al. Management of small cell lung cancer: recent developments for optimal care[J].Drugs, 2012:72(4):471-490.
